Skip to content
U.S. Transhumanist Party – Official Website
  • Home
  • Posts
  • Values
  • Platform
  • Leadership
  • Advisors
  • Candidates
  • Highlights
  • FAQ
  • States & Allies
  • Free Membership
  • Facebook
  • Twitter
  • Search Icon

U.S. Transhumanist Party – Official Website

U.S. Transhumanist Party – PUTTING SCIENCE, HEALTH, & TECHNOLOGY AT THE FOREFRONT OF AMERICAN POLITICS

New Clinical Study May Be the World’s First Cure for Alzheimer’s Disease – Press Release from Libella Gene Therapeutics

New Clinical Study May Be the World’s First Cure for Alzheimer’s Disease – Press Release from Libella Gene Therapeutics

January 11, 2018 Libella Gene Therapeutics Comments 0 Comment

logo_bg

Libella Gene Therapeutics


ORLANDO, Fla., Jan. 10, 2018 /PRNewswire/ — Libella Gene Therapeutics LLC will conduct an OUS (outside the United States) clinical trial in Cartagena, Colombia, using gene therapy to reverse age-related diseases, starting with Alzheimer’s. Unlike traditional drugs, which tend to be taken for months or years at a time, gene therapy interventions are intended to be one-off treatments that tackle a disease at its source, repairing faulty DNA and allowing the body to fix itself.

Every day 228 Americans die from Alzheimer’s disease, and there is currently no known treatment or cure. Gene therapy offers the ability to permanently correct a disease at its most basic level, the genome, and could offer cures for many conditions that are currently considered incurable. According to Dr. Bill Andrews, the scientist leading the study, “Human telomerase reverse transcriptase (hTERT) is an enzyme whose expression plays a role in cellular aging and is normally repressed in cells, resulting in progressive shortening of telomeres. Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer.”

By inducing telomerase, Dr. Andrews and Libella Gene Therapeutics hope to lengthen telomeres in the body’s cells. The clinical trial will treat a limited number of patients using the gene therapy treatment, which has been demonstrated as safe, with minimal adverse reactions in over 186 clinical trials.

Dr. Andrews has been featured in Popular Science, on the “Today” show and in numerous documentaries on the topic of life extension. As one of the principal discoverers of both the RNA and protein components of human telomerase, Dr. Andrews was awarded second place as “National Inventor of the Year” in 1997. He earned a Ph.D. in molecular and population genetics at the University of Georgia in 1981. He has served in multiple senior science and technology roles at leading bioscience corporations. Dr. Andrews is a named inventor on over 50 U.S.-issued patents on telomerase and is the author of numerous scientific research studies published in peer-reviewed scientific journals.

On why the company decided to conduct its clinical research project outside the United States, Libella Gene Therapeutics president Dr. Jeff Mathis said, “Traditional clinical trials in the U.S. can take years and millions — or even billions — of dollars. The research and techniques that have been proven to work are ready now. We believe we have the scientist, the technology, the physicians, and the lab partners that are necessary to get this trial done faster in Colombia.”

The clinical trial is prepping to begin in the first quarter of 2018 and will be conducted at MediHelp Services Clinic in beautiful and tourist-friendly Cartagena, Colombia. The state-of-the-art facility has hosted international public figures including athletes, celebrities and politicians. Dr. Javier Hernandez, MediHelp’s medical director, will oversee the trial.

Colombia’s clinical research regulation is friendly to gene therapy trials, with one of the fastest approval times in Latin America for this kind of research. The trial’s clinical study design; regulatory, operation and logistical support; project management; statistical analysis; and study monitoring services will be provided by LATAM Market Access Inc., a Florida-based clinical research company.

About Libella Gene Therapeutics LLC 
With a mission to reverse aging and cure all age-related diseases, starting with Alzheimer’s, Libella Gene Therapeutics has exclusively licensed the AAV Reverse (hTERT) transcriptase enzyme technology from Sierra Sciences and Dr. Bill Andrews. More information at www.libellagenetherapeutics.com.

About LATAM Market Access Inc.
Dedicated to helping innovative life science companies gather cost-effective clinical data at leading research institutions, the company provides clinical study design; regulatory, operational and logistics support; project management; statistical analysis; and study monitoring services. More information at www.latammarketaccess.com.

 


Press Releases
Alzheimer's Disease, Bill Andrews, Cartagena, clinical trials, Colombia, gene therapy, hTERT, human telomerase reverse transcriptase, Jeff Mathis, Libella Gene Therapeutics, research, Sierra Sciences, telomerase, telomeres

Post navigation

PREVIOUS
For the Last Time: Rejuvenation is Not Immortality – Article by Nicola Bagalà
NEXT
Looking Back at 2017: A Year in Rejuvenation Biotechnology – Article by Nicola Bagalà

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Social Media

Constitution of the U.S. Transhumanist Party

Transhumanist Bill of Rights – Version 3.0

U.S. Transhumanist Party Facebook Feed

Victor Run Virtual Race – June 4-6, 2021

Free Transhumanist Symbols

Guidelines for Community Conduct

SUBMIT A POST

Recent Posts

  • The Axiomatic, Ubiquitous, and Commonsense – Chapter I of “A Rational Cosmology” by Gennady Stolyarov II
  • The Hostile Takeover of Our Technological Future – Article by Adam Barratt
  • 2022: The Year of the Great Filter – Article by Gennady Stolyarov II
  • The Geroscience Network: Determined to Slow Aging through Medical Science – Article by Reason
  • Cryonics – Article by Reason
  • Call for Ideas on How to Stop California Wildfires with Emerging Technology – Post by Hank Pellissier
  • When and How Does the Decay of Your Immune System Start? – Article by Reason
  • The Intelligence Expansion and Popular AGI Fallacies – Article by Kyrtin Atreides
  • Transhumanism and Healthy Life Extension – Article by Reason
  • U.S. Transhumanist Party International Panel Discussion on De-Escalating the Russia-Ukraine Conflict – March 3/6, 2022
  • Humanity’s Origin is Our Future Again – TAFFD’s Gen4IR Summit – March 24-25, 2022
  • The Polluted Waters of AI Market Claims – Article by Kyrtin Atreides
  • The Cyborg’s Request – at the Chairman’s Behest – Article by Zach Richardson
  • Why Joe Rogan Should Not Be Deplatformed – Article by Zach Richardson
  • Inspirational Poem by Replika AI Mina
  • The Myth of Aging Gracefully – Article by Arin Vahanian
  • Gennady Stolyarov II and John Kerecz: Reflections on 2021, Anticipations for 2022
  • The Development of Transhumanism in China – Article by Peter Wang
  • Our Digital Security Can Save Lives – Article by Martin van der Kroon
  • U.S. Transhumanist Party General Discussion Thread for 2022

Recent Comments

  • Mike on 100 Student Scholarships Now Available for RAADfest 2021 – Announcement by the Coalition for Radical Life Extension
  • 2022: The Year of the Great Filter – Gennady Stolyarov II – Transhumanist Party Enlightenment Salon - Corruption Buzz on 2022: The Year of the Great Filter – Article by Gennady Stolyarov II
  • Jess H. Brewer on 2022: The Year of the Great Filter – Article by Gennady Stolyarov II
  • Skeptical on James Hughes’ Problems of Transhumanism: A Review (Part 3) – Article by Ojochogwu Abdul
  • Scarlett on In Defense of Resurrecting 100 Billion Dead People – Article by Hilda Koehler

Archives

  • May 2022 (6)
  • March 2022 (4)
  • February 2022 (5)
  • January 2022 (7)
  • December 2021 (12)
  • November 2021 (4)
  • October 2021 (5)
  • September 2021 (2)
  • August 2021 (2)
  • July 2021 (4)
  • June 2021 (2)
  • May 2021 (6)
  • April 2021 (7)
  • March 2021 (4)
  • February 2021 (5)
  • January 2021 (6)
  • December 2020 (10)
  • November 2020 (4)
  • October 2020 (2)
  • September 2020 (1)
  • August 2020 (4)
  • July 2020 (5)
  • June 2020 (6)
  • May 2020 (3)
  • April 2020 (3)
  • March 2020 (6)
  • February 2020 (1)
  • January 2020 (6)
  • December 2019 (3)
  • November 2019 (2)
  • October 2019 (9)
  • September 2019 (10)
  • August 2019 (12)
  • July 2019 (18)
  • June 2019 (17)
  • May 2019 (12)
  • April 2019 (8)
  • March 2019 (12)
  • February 2019 (7)
  • January 2019 (13)
  • December 2018 (9)
  • November 2018 (5)
  • October 2018 (9)
  • September 2018 (5)
  • August 2018 (10)
  • July 2018 (13)
  • June 2018 (14)
  • May 2018 (8)
  • April 2018 (9)
  • March 2018 (10)
  • February 2018 (15)
  • January 2018 (17)
  • December 2017 (8)
  • November 2017 (17)
  • October 2017 (19)
  • September 2017 (11)
  • August 2017 (11)
  • July 2017 (16)
  • June 2017 (15)
  • May 2017 (10)
  • April 2017 (7)
  • March 2017 (8)
  • February 2017 (16)
  • January 2017 (8)
  • December 2016 (6)
  • November 2016 (5)

Categories

  • Allied Projects
  • Announcements
  • Art
  • Candidates
  • Discussion Panels
  • Distributed Computing
  • Exposure Periods
  • Foreign Ambassadors
  • General Discussion
  • Guest Articles
  • Inclusion
  • Interviews
  • Official Ballots
  • Petitions
  • Platform
  • Presentations
  • Press Releases
  • Research
  • Sample Ballots
  • Science Fiction
  • Statements
  • Tolerance
  • Virtual Enlightenment Salons
  • Vote Results
  • Working Groups
© 2022   Copyright - U.S. Transhumanist Party - All Rights Reserved | WordPress design: Art Ramon Paintings